-
President, Medicine & Science traces journey through diabetes
Mandeep Bajaj, MBBS, shared the path through Northern Ireland, India, and the U.S. that led to a career focus on hepatic fat, liver fibrosis, and what is now known as metabolic dysfunction-associated steatohepatitis (MASH).
-
Dietitians explore how a CDCES can help optimize outcomes with GLP-1-based therapies
With more incretin therapies anticipated for diabetes and obesity soon, experts including Maureen Chomko, RD, CDCES, discussed how dietitians and certified diabetes care and education specialists (CDCES) can help patients get the most benefit from these agents.
-
Experts illuminate various forms of intermittent fasting in diabetes care and beyond
Time-restricted eating has been found to improve cardiometabolic health, insulin resistance, glycemic management, and blood pressure independent of weight loss. It can even affect polycystic ovary syndrome (PCOS), explained Sofia Cienfuegos, PhD, MS.
-
Symposium presented by Diabetes, Diabetes Care, and Diabetologia will spotlight the heterogeneity of type 1 diabetes
Developed by leading investigators in the field in a closed-door expert forum earlier in the week, the program will take a bench-to-bedside perspective, reviewing what is currently known and identify knowledge gaps with the aim of spurring future research and translation of emerging concepts.
-
Outstanding Educator explains how collaboration with patients can improve outcomes
The ADA’s Outstanding Educator in Diabetes for 2024, Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, had his understanding of the disease reframed when he was diagnosed with type 1 diabetes as a graduate student.
-
ADA President, Health Care & Education outlines lessons learned in diabetes education
Patti Urbanski, MEd, RD, LD, CDCES, FADCES, highlighted research on the effectiveness of diabetes education, weaving in her personal experience as a person with type 1 diabetes and as a diabetes educator.
-
New results from SELECT show reduction in progression to diabetes
Semaglutide is best known as a weight loss drug, yet SELECT was not a weight loss study. It was a secondary cardioprevention trial, explained Donna H. Ryan, MD, one of the experts presenting results from SELECT.
-
SURMOUNT-OSA findings demonstrate benefit of tirzepatide in treatment of obesity-related OSA
The drug has been shown to improve sleep apnea severity and related cardiometabolic issues in people with moderate-to-severe obstructive sleep apnea, reported investigators including Atul Malhotra, MD, and Louis J. Aronne, MD, FACP, DABOM.
-
INHALE-3 investigators detail benefits of inhaled insulin for type 1 diabetes
Study Chair Irl B. Hirsch, MD, reported that inhaled insulin may be good for patients who are engaged in their diabetes self-management and want to reduce hyperglycemia even further, and for patients who want an alternative to a pump.
-
Diabetes symposium will elucidate the key role of the central nervous system in metabolic control
“The role of the central nervous system (CNS) in metabolic regulation has important implications for normal physiology and for disease, and this symposium was constructed to highlight how these may contribute to diabetes,” said Diabetes® Editor in Chief David A. D’Alessio, MD.